AAM
BPMC

Alpine Associates Management’s Blueprint Medicines BPMC Stock Holding History

Alpine Associates Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,060,307
Closed -$136M – 74
2025
Q2 		$136M Buy
+1,060,307
New +$110M 7.25% 3

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Alpine Associates Management's BPMC Position: Q3 2025 in Review

Alpine Associates Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,060,307 shares — an estimated $136M sold.

Alpine Associates Management first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $136M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Alpine Associates Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Alpine Associates Management sold 1,060,307 Blueprint Medicines shares in Q3 2025, an estimated $136M.
  • Alpine Associates Management first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
  • Alpine Associates Management's Blueprint Medicines position peaked at $136M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Alpine Associates Management's 13F filing for Q3 2025, filed 6 Nov 2025.